Clinical Trial: A Phase II Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07604064) titled 'A Phase II Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia' on May 18.

Brief Summary: This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia

Intervention: DRUG: Olutasidenib

Olutasidenib: Oral administrat...